Limited Time OfferSave up to $400 on your first GLP-1 order
Decision Guide

Semaglutide vs. Tirzepatide: Which GLP-1 Should You Choose? (The Buyer's Decision Guide)

Julian Mercer
Lead Bio-Systems Analyst · Updated May 2026 · 18 min read
Semaglutide pen vs tirzepatide pen with decision scale

You know you want GLP-1 medication. You know it works. The question is: which one? Semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound)? This is not a pharmacology lecture — it is a decision framework. By the end, you will know which one is right for your situation.

The Quick Decision Matrix

Your SituationBest ChoiceWhy
Budget is primary concernSemaglutide$199/mo compounded vs $349/mo
Maximum weight loss is priorityTirzepatide22.5% vs 14.9% body weight loss
Significant insulin resistance/prediabetesTirzepatideDual GIP/GLP-1 = superior insulin effect
Prefer more long-term safety dataSemaglutideOn market since 2017 vs 2022
Plateaued on semaglutideSwitch to tirzepatideDifferent mechanism may break plateau
BMI 40+ with comorbiditiesTirzepatideSURMOUNT showed strongest results at higher BMI
Not sure / first-time GLP-1Let clinician decideBased on metabolic profile, labs, goals

Head-to-Head Clinical Data

MetricSemaglutide (STEP)Tirzepatide (SURMOUNT)
Avg weight loss (max dose)14.9%22.5%
MechanismGLP-1 onlyGLP-1 + GIP (dual)
Injection frequencyOnce weeklyOnce weekly
Nausea rate~44%~29%
Compounded price$199–$399/mo$349–$499/mo
Years on market9 years (since 2017)4 years (since 2022)

Not Sure? Let Your Clinician Decide.

TelehealthFX offers both compounded semaglutide and tirzepatide. Your clinician recommends the right one based on your metabolic profile — not a one-size-fits-all protocol.

Start Your Evaluation

Frequently Asked Questions

Can I switch from semaglutide to tirzepatide?

Yes. Switching is common, especially when patients hit a weight loss plateau. Your clinician will determine the appropriate starting dose of tirzepatide based on your current semaglutide dose.

Is tirzepatide really 50% more effective?

In clinical trials, yes. SURMOUNT-1 showed 22.5% average weight loss at 15 mg vs. STEP-1's 14.9% at 2.4 mg semaglutide. Individual results vary. See the tirzepatide results timeline.

Both Available. You Choose With Your Clinician.

Semaglutide from $199/mo. Tirzepatide from $349/mo. Same platform, same clinician.

Get Started

References

  1. Wilding, J. P. H., et al. (2021). STEP 1. NEJM, 384(11), 989–1002.
  2. Jastreboff, A. M., et al. (2022). SURMOUNT-1. NEJM, 387(3), 205–216.